Eli Lilly (NY:LLY)

Should You Buy the Vanguard S&P 500 ETF With the Stock Market Near a Record High? History Offers a Clear Answer ↗

Topics Earnings Economy

February 17, 2026

Despite recent volatility, trends like artificial intelligence could fuel another strong year for the stock market.

Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗

Topics Artificial Intelligence ETFs Stocks

Eli Lilly & Co (NYSE:LLY) Combines Explosive Growth with a Bullish Technical Setup ↗

February 17, 2026

Via Chartmill

February 17, 2026

Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline.

Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million ↗

Topics Regulatory Compliance

February 17, 2026

This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications.

Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors.

Topics Regulatory Compliance

Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗

February 17, 2026

Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs.

Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗

February 17, 2026

A robust pipeline is essential for a buy-and-hold pharmaceutical stock.

1 Reason I'd Buy Eli Lilly Stock and Never Sell ↗

February 17, 2026

As of February 17, 2026, the biotechnology sector is undergoing its most significant structural transformation in decades, a period now widely termed the "Biotechnology Renaissance." Following a...

Topics Intellectual Property

The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot

February 17, 2026

NVO Stock Generates Retail Buzz After European Commission Approves 7.2 MG Once-Weekly Dose Of Wegovy Injection ↗

Topics Artificial Intelligence Economy Initial Public Offering

February 17, 2026

The approval follows a positive recommendation from the European Medicines Agency and is supported by data from clinical trials involving more than 1,400 participants.

Novo Nordisk and the FDA are both mounting pressure on Hims & Hers Health and other GLP-1 compounders.

Topics Lawsuit

Hims & Hers Faces New Hurdle In Weight-Loss Brawl With Novo Nordisk ↗

February 17, 2026

Via Investor's Business Daily

Topics Lawsuit

2026 Could Be a Big Year for Viking Therapeutics. Time to Buy? ↗

February 17, 2026

Viking should have plenty of news to share with investors this year.

Eli Lilly's Experimental Cancer Drug Cuts Recurrence Risk In Early-Stage Lung Cancer Patients ↗

February 17, 2026

Eli Lilly's lung cancer trial shows lower recurrence risk and strong survival benefit in early-stage patients.

Via Benzinga

Nasdaq, S&P 500 Futures Lower As AI Disruption Fears Linger: Why AAPL, ZIM, OCUL, NCLH Are On Traders' Radar Today ↗

February 17, 2026

Wall Street resumed trade after the Presidents’ Day break to find a market still grappling with the ‘AI disruption’ trade.

Novo Nordisk's plan to gain ground in the GLP-1 space is slowly taking shape.

Topics Artificial Intelligence ETFs Economy

Novo Nordisk's New Diabetes Drug Outshines Ozempic: Is The Stock a Buy? ↗

February 16, 2026

Lamb Weston is a global leader in frozen potato products, serving both retail and foodservice markets with a diversified brand portfolio.

Liberty One Cuts Its Lamb Weston Position in Half With $32 Million Sale ↗

February 16, 2026

And there's more than one way to monetize this technology.

Topics Economy Regulatory Compliance Supply Chain

Forget AI Stocks: This Pharma Giant Is Using AI to Dominate Drug Discovery ↗

February 15, 2026

The Smartest Growth ETF to Buy With $1,000 Right Now. (Hint: It Has Averaged Annual Gains of 18.6% Over the Past 10 Years.) ↗

Topics Artificial Intelligence

February 15, 2026

It's an easy way to quickly own 150-plus companies growing at a solid clip.

Eli Lilly Just Delivered Great News for Investors -- and It Goes Beyond Weight-Loss Drugs ↗

Topics ETFs

February 15, 2026

Eli Lilly isn't a one-trick pony.

Eli Lilly continues to pursue smart acquisitions for the long term.

What Is One of the Best Pharmaceutical Stocks to Own for the Next 10 Years? ↗

February 14, 2026

Topics Intellectual Property

Got $500? 2 Pharma Stocks to Buy and Hold Forever. ↗

February 14, 2026

Growth, value, or both?

Novo Nordisk To Meet Wegovy Pill Demand In US Before Expanding To Avoid Supply Shortage, Says CEO Doustdar ↗

February 13, 2026

Novo is looking to ensure the U.S. market is supplied before choosing another country to scale in, Doustdar said in an interview with CNBC.

The U.S. labor market kicked off 2026 with an unexpected surge, as the January nonfarm payrolls report shattered analyst expectations and provided a much-needed jolt to the economic outlook. Adding...

Topics Lawsuit

"Blowout" Jobs Report Ignites 2026 Growth Hopes as Unemployment Hits 4.3% Floor

February 13, 2026

Hospitals Stand Tall: Healthcare Sector Becomes Safe Haven Amid "Warsh Shock" and Tech Volatility

Topics Artificial Intelligence Economy Workforce

February 13, 2026

In a day defined by sharp reversals and a fundamental recalibration of market leadership, the healthcare sector emerged as the primary beneficiary of a massive capital rotation on February 13, 2026....

Eli Lilly announced an acquisition of an innovative new autoimmune drug.

Topics Artificial Intelligence Earnings Economy

Did Eli Lilly Just Make a Deal for Its Next Blockbuster Drug? ↗

February 13, 2026

The Great 2026 Divergence: Tech Titans Rise on AI Execution While Healthcare Reaps a Regulatory Whirlwind

February 13, 2026

As the opening bell rang on February 13, 2026, the divergence between the U.S. technology and healthcare sectors reached a historic fever pitch, signaling a fundamental shift in how markets price...

Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.

Topics Artificial Intelligence Economy Intellectual Property

Meet the 6.3% Yield Dividend Stock That Could Soar in 2026 ↗

February 13, 2026

Eli Lilly Builds $1.5 Billion Inventory Of Experimental Weight-Loss Pill As FDA Decision Looms ↗

Topics Intellectual Property

February 13, 2026

Eli Lilly and Company (NYSE: LLY) has stockpiled $1.5 billion worth of inventory of its experimental oral weight-loss drug, orforglipron, according to a regulatory filing on Thursday.

Via Benzinga

Nasdaq, S&P 500 Futures Edge Lower Ahead Of CPI Data: Why NVDA, AAPL, TSLA, RIVN, MRNA, AMAT, IREN Are On Traders' Radar Today ↗

February 13, 2026

Data on Stocktwits showed retail traders remained bearish on SPY and ‘extremely bearish’ on QQQ.

Meta Platforms Breaks Ground on Massive $10 Billion Indiana Data Center: A Giant Leap Toward 'Personal Superintelligence'

Topics Bonds ETFs Economy

February 12, 2026

On February 11, 2026, Meta Platforms Inc. (NASDAQ: META) officially broke ground on a sprawling $10 billion data center campus in Lebanon, Indiana, marking a monumental shift in the company’s...